BridgeBio Oncology Therapeutics, Inc. Asset Resilience Ratio
BridgeBio Oncology Therapeutics, Inc. asset resilience ratio. BridgeBio Oncology Therapeutics, Inc. (BBOT) has an Asset Resilience Ratio of 47.80% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can BridgeBio Oncology Therapeutics, Inc. fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BridgeBio Oncology Therapeutics, Inc. (2024–2025)
Asset resilience ratio of BridgeBio Oncology Therapeutics, Inc. from 2024 to 2025. This chart shows how BridgeBio Oncology Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read BridgeBio Oncology Therapeutics, Inc. (BBOT) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BridgeBio Oncology Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BridgeBio Oncology Therapeutics, Inc. total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $199.62 Million | 47.8% |
| Total Liquid Assets | $199.62 Million | 47.80% |
Asset Resilience Insights
- Very High Liquidity: BridgeBio Oncology Therapeutics, Inc. maintains exceptional liquid asset reserves at 47.80% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BridgeBio Oncology Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare BridgeBio Oncology Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
BridgeBio Oncology Therapeutics, Inc. Asset Resilience Ratio by Year (2024–2025)
BridgeBio Oncology Therapeutics, Inc. asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for BridgeBio Oncology Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.55% | $51.77 Million | $448.38 Million | -52.63pp |
| 2024-12-31 | 64.18% | $124.78 Million | $194.42 Million | -- |
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more